Publication

Video

Supplements and Featured Publications

Milestones in Medicine: History & Evolving Role of Interferon in Myeloproliferative Neoplasms
Volume1
Issue 1

Dr. Kiladjian on the RUXOPeg Trial in Myelofibrosis

Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology, Paris Diderot University, consultant hematologist, head, Clinical Investigation Center, Saint Louis Hospital, Paris, France, discusses the RUXOPeg trial in myelofibrosis.

Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology, Paris Diderot University, consultant hematologist, head, Clinical Investigation Center, Saint Louis Hospital, Paris, France, discusses the RUXOPeg trial in myelofibrosis.

The RUXOPeg trial examined the combination of ruxolitinib (Jakafi) and pegylated interferon alfa-2a (Pegasys) in patients with myelofibrosis, explains Kiladjian. Although ruxolitinib has not been shown to affect the disease history of myelofibrosis, interferon has demonstrated reduced molecular response and clinicohematologic responses. However, the agent has a high toxicity profile, says Kiladjian. If ruxolitinib’s anti-inflammatory properties could counteract the toxicity of interferon, it was believed that the combination could improve the rate of molecular response and clinicohematologic responses.

According to results presented at the 2018 ASH Annual Meeting, the combination was well tolerated. In the first 16 patients enrolled in this study, there were no dose-limiting toxicities, says Kiladjian. Based on these results, investigators are planning to proceed to the second part of the study, which will randomize patients to the 2 highest dose combinations in order to further assess the combination’s efficacy.

Related Videos
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.